Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 12/20 | 0.43 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | PRKACA | P17612 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.39 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7661702 | 0.89 | BRAF (0.43) | BRAFNUDT1CDK1PRKACAHDAC1 | |
| SCHEMBL5474432 | 0.78 | CDK1 (0.42) | BRAFNUDT1CDK1PRKACAHDAC1 | |
| SCHEMBL5472025 | 0.78 | CDK1 (0.42) | BRAFNUDT1CDK1PRKACAHDAC1 | |
| SCHEMBL133157 | 0.71 | LMNA (0.54) | BRAFNUDT1CDK1PDPK1GDA | |
| SCHEMBL7621600 | 0.69 | LMNA (0.62) | CDK1PDPK1GDA | |
| SCHEMBL7626878 | 0.69 | LMNA (0.58) | CDK1PDPK1GDA | |
| 2,6-Diaminopurine SCHEMBL7801065 | 0.69 | PDPK1 (0.55) | CDK1PDPK1GDA | |
| SCHEMBL3396378 | 0.69 | PDPK1 (0.61) | BRAFNUDT1CDK1PRKACAPDPK1 | |
| SCHEMBL797051 | 0.68 | LMNA (0.63) | CDK1 | |
| SCHEMBL2938906 | 0.68 | PDPK1 (0.59) | BRAFNUDT1CDK1PRKACAHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070065922-A1 | Biocatalytic synthesis of aminodeoxy purine N9-beta-D-nucleosides containing 3-amino-3-deoxy-beta-D-ribofuranose, 3-amino-2,3-dideoxy-beta-D-ribofuranose, and 2-amino-2-deoxy-beta-D-ribofuranose as sugar moieties | METKINEN OY (FI) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070065922-A1 | Biocatalytic synthesis of aminodeoxy purine N9-beta-D-nucleosides containing 3-amino-3-deoxy-beta-D-ribofuranose, 3-amino-2,3-dideoxy-beta-D-ribofuranose, and 2-amino-2-deoxy-beta-D-ribofuranose as sugar moieties | DUT, UNG, GALE | BRAF 2221/4885NUDT1 81/4885CDK1 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.